INTRODUCTION
Cancer of the uterine cervix that has metastasized or recurred at sites not amenable to treatment by surgery or radiation portends a grim prognosis. 1 No potentially curative therapy yet exists. The focus of treatment has been palliation with chemotherapy. 2 The Gynecologic Oncology Group (GOG) has conducted multiple phase II trials in search of active agents against cervical cancer. To date, cisplatin, ifosfamide, paclitaxel, topotecan, vinorelbine, gemcitabine, pemetrexed, and bevacizumab have been found to have activity of interest as single agents or in combinations. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Combinations of these agents have been compared with improvements in response rates. 16 However, only recently has an improvement in survival been seen with cisplatin and topotecan over cisplatin alone and with the addition of bevacizumab to cisplatin and paclitaxel. 17, 18 Pemetrexed (Alimta, LY231514; Eli Lilly, Indianapolis, IN) is an antifolate, antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. Pemetrexed targets thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.
single-institution trial in chemotherapy-naive patients with cervical cancer and two trials in previously treated patients suggested possible activity for pemetrexed alone. 15, 20, 21 The objectives of this trial (Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer [GOG-0076GG]) were to estimate the antitumor activity of pemetrexed and cisplatin with objective tumor response (partial response [PR] and complete response [CR] ) in patients with advanced, persistent, or recurrent carcinoma of the cervix; to determine the nature and degree of toxicity of pemetrexed and cisplatin in this cohort of patients; and to determine the effects of this regimen on progression-free survival (PFS) and overall survival (OS).
PATIENTS AND METHODS

Eligibility
To be eligible for the trial, patients must have had advanced, persistent, or recurrent squamous or nonsquamous cell carcinoma of the cervix not amenable to curative therapy. Patients who had prior therapy with cytotoxic drugs for advanced and/or recurrent cervical carcinoma were ineligible. Patients who had prior cisplatin as a radiosensitizer for primary treatment of disease were eligible. Histologic documentation of the original primary tumor was required via the pathology report. All patients must have had measurable disease defined as at least one lesion that could be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must have been Ն 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography, and magnetic resonance imaging, or Ն 10 mm when measured by spiral computed tomography. Patients must have had at least one target lesion that was used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.0.
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Tumors within a previously irradiated field were designated as "nontarget" lesions unless progression was documented or a biopsy was obtained to confirm persistence at least 90 days after completion of radiotherapy (RT). Patients must have had a GOG performance status (PS) of 0, 1, or 2 and must have been free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infections). Any hormonal therapy directed at the malignant tumor must have been discontinued at least 1 week before registration. Continuation of hormone replacement therapy was permitted. Any prior RT must have been discontinued at least 4 weeks before registration. Female patients of childbearing age must have had a negative serum pregnancy test before the study entry and be practicing an effective form of contraception. All patients provided signed informed consent consistent with all local, state, and federal guidelines; the institutional review board at each participating institution provided approval.
Pemetrexed at a dose of 500 mg/m 2 was to be administered as an intravenous (IV) infusion over 10 minutes immediately followed by cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of 50 mg/m 2 every 21 days. Seven days before initiation of pemetrexed, patients were to begin taking folic acid at a dose of 350 to 600 mcg daily and to receive an intramuscular injection of 1,000 mcg of vitamin B 12 to be repeated every 3 months during therapy. Dexamethasone 4 mg by mouth twice per day was taken the day prior to, day of, and day after each dose of pemetrexed. Nonsteroidal anti-inflammatory drugs were held for the 2 days before and after pemetrexed administration. Complete blood counts were obtained once per week. Cycles were to be repeated every 21 days pending an absolute neutrophil count more than 1,500/mL, platelet count more than 100,000/mL, and resolution of nonhematologic toxicities. Weekly delays in therapy were prescribed to allow resolution of persistent hematologic and nonhematologic toxicity. However, patients were removed from study for delays in excess of 2 weeks. This study used the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 for defining and grading specific adverse events (AEs).
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Dose reduction was required for febrile neutropenia and/or grade 4 neutropenia persisting more than 7 days, grade 4 thrombocytopenia, or grade 2 bleeding, and peripheral neuropathy greater than grade 2. Prophylactic growth factors were not allowed unless patients experienced recurrent neutropenic complications after prescribed treatment delays. Use of erythropoietin was allowed. If AEs were not severe, patients remained on pemetrexed until evidence of disease progression or unacceptable toxicity. Cisplatin was continued up to a maximum of six cycles. Patients with continued response or with stable disease (SD) could continue receiving cisplatin beyond the six cycles with the consent of the study chair.
Statistical Design
The protocol used a two-stage group sequential design with stratification on prior cisplatin as a radiation sensitizer. On the basis of prior GOG studies, 16 ,17,24 the response rate of interest was 40% for those patients who had not received prior cis-RT (stratum 1), whereas it was only 25% in those patients who had received prior cis-RT (stratum 2). This study involved a mixture of these two strata. Therefore, a two-stage stratified design as proposed by London and Chiang was used. 23 This design uses the marginal number of responses across all strata while factoring differing probabilities of response within each stratum. The null hypothesis of no treatment effect is H 0 : p 1 ϭ 0.20 and p 2 ϭ 0.10. The alternative hypothesis is H 1 : p 1 ϭ 0.40 and p 2 ϭ 0.25. The targeted accrual for the first stage of accrual was 26 patients. The distribution of the two strata could not be determined beforehand; therefore, the required number of responses to proceed with the second stage varied with the realized distribution. Tables were generated for all contingencies. If the study proceeded to the second stage of accrual, at least 49 cumulative patients would be entered. Again, the distribution of the two responses necessitated multiple decision rules. The probabilities of type 1 and type 2 errors were approximately 0.10. Of note, response rates in the individual strata are not the focus of the decision rule. Rather, it is based on the observed responses in the overall sample.
RESULTS
From September 2008 to November 2011, 55 patients were entered onto this limited access trial by five member institutions of the GOG. One patient did not receive any treatment and was inevaluable (Fig 1) . The characteristics of the 54 evaluable patients are presented in Table  1 . The median age of patients treated was 46 years. Most patients had a PS of 0 (63%), were white (54%), and had squamous histology (80%). No patients had received prior tumor-directed chemotherapy, and 65% had prior RT with 77% of those receiving chemoradiotherapy. A total of 333 cycles (average per patient, 6.2 cycles; range, one to 20 cycles) of chemotherapy were administered with 29% of patients receiving nine or more cycles.
Toxicities for all patients are listed in Table 2 . Overall, the treatment was well tolerated with the most common toxicities being anemia, GI, constitutional, and nausea. More serious toxicities (grade 3 and 4) included neutropenia 35%, leukopenia 28%, and metabolic 28%. Dose reduction of both cisplatin and pemetrexed as a result of toxicity was required in five patients (9%) and of cisplatin in only three patients (6%). No treatment-related deaths were reported.
In the first stage of accrual, there were 19 patients from stratum 1 and 10 from stratum 2. We observed nine responses, and the study proceeded to the second stage. The overall response rate was 31% (one CR and 16 PRs; 95% CI, 19.5% to 45.6%) for a median duration of response of 7.6 months ( Table 3 ). All 17 of the responses were seen in the 45 patients with measurable tumor in nonradiated disease sites; no responses were seen in the nine patients with measurable tumor in irradiated disease sites. The response rate for nonradiated disease sites was 38% (95% CI, 23.8% to 53.5%; 17 of 45). There were 14 responses (33%) seen in the 43 patients with squamous histology and three (27%) in the 11 patients with adenocarcinoma. Seven responses (26%) were seen in the 27 patients who had received cisplatin with their RT and 10 (37%) responses were seen in 27 patients who had not. SD was seen in 44% for a median of 5.1 months (range, 2.3 to 18.6 months), and increasing disease was seen in 15%. Response could not be assessed in five patients (9%). Median PFS was 5.7 months (range, 0.3 to 38.6 months) and median OS was 12.3 months (range, 0.3 to 38.6 months; Fig 2) .
DISCUSSION
Cisplatin and pemetrexed is an active first-line regimen against advanced, recurrent, or persistent cervical carcinoma. The treatment was well tolerated.
Early phase II trials by the GOG had identified several potentially active agents including cisplatin and ifosfamide. [3] [4] [5] Several of these drugs were combined and, in some cases, showed increased activity.
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Although some progress was made toward palliating patients, the search for active agents continued. The GOG then embarked on a series of phase II protocols (GOG-0127 and GOG-0128) evaluating new agents or novel combinations of agents in patients with advanced or recurrent cervical cancer for whom prior chemotherapy had failed. Several potentially active agents were identified, including topotecan, cisplatin plus gemcitabine, and vinorelbine. [7] [8] [9] 11, 27 In addition, potentially active agents and combinations were tested in the first-line setting in the GOG-0076 series. Ifosfamide, paclitaxel, topotecan, paclitaxel plus cisplatin, and cisplatin plus vinorelbine showed activity of interest. [12] [13] [14] 28, 29 Several of the agents and combinations found to have activity of interest in the GOG-0076, GOG-0127, and GOG-0128 series of protocols were compared in phase III trials. Cisplatin plus paclitaxel was superior to cisplatin alone with respect to response rate and PFS with sustained quality of life. 16 Cisplatin plus topotecan was used in the first randomized phase III trial to demonstrate a survival advantage for combination chemotherapy over cisplatin alone in advanced cervical cancer.
17,30,31 Paclitaxel, topotecan, gemcitabine, and vinorelbine were each combined with cisplatin in a randomized firstline trial (GOG-0204). None of the other combinations were superior to cisplatin plus paclitaxel.
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Pemetrexed is a third-generation antifolate-containing pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication.
19,32 Unlike older agents that target a single enzyme, pemetrexed targets multiple enzymes: thymidylate synthase (TS), glycinamide ribonucleotide formyltransferase (GARFT), 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT), and dihydrofolate reductase (DHFR). 33 Pemetrexed enters the cell through the reduced folate carrier, which is the major transporter for folates and is also a substrate for the folate receptoralpha (FR-␣). 34 A low-pH transporter may also be involved in pemetrexed internalization. 35 Pemetrexed is activated intracellularly to a polyglutamated form, with the pentaglutamated form being most active. 33 Pentaglutamated pemetrexed potently inhibits TS and also inhibits GARFT and AICARFT but has a low affinity for DHFR.
32,33
Enhanced expression of TS mediates resistance of uterine cervical cancer cells to radiation and has been associated with a poor prognosis in patients with cervical cancer.
36,37 Pemetrexed enhanced radiationinduced cell inactivation in cervical cancer cell lines (HeLa cells).
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On the basis of multivariable analyses of toxicities observed in early pemetrexed trials, plasma levels of homocysteine and methylmalonic acid were identified as predictive variables for pemetrexedassociated toxicity.
39 Folic acid and vitamin B 12 supplementation caused a statistically significant reduction in plasma homocysteine concentrations over time and a significant reduction in the frequencies of severe hematologic toxicities and nonhematologic toxicities, such as mucositis, in patients receiving pemetrexed therapy. 40 On the basis of the biologic rationale as well as its activity in other squamous cell cancers, pemetrexed has been tested in three single-arm phase II trials in patients with cervical cancer. One trial involved chemotherapy-naive patients, and two trials investigated the agent as second-line therapy.
Goedhals et al 20 treated 35 chemotherapy-naive patients with stages III and IV cervical squamous cell carcinoma. Patients received pemetrexed 600 mg/m 2 every 21 days, without vitamins, but the dose was subsequently reduced to 500 mg/m 2 . Responses were reported in 18% of the patients with a median duration of 4 months.
The GOG evaluated pemetrexed (900 mg/m 2 every 21 days with folic acid and vitamin B 12 ) as second-line therapy in patients with persistent or recurrent carcinoma of the cervix (GOG-0127T). Prior platinum-based chemotherapy was received by all, and prior RT was received by most patients (85%). Patients received a median of four (range, one to 10) cycles, with 37% of patients receiving six or more cycles. Four patients (15%; 95% CI, 4.2% to 33.7%) experienced a PR with a median duration of 4.4 months. The rate for SD was 59%. The response rates for irradiated and nonirradiated disease sites were 7% and 25%, respectively. The median PFS was 3.1 months (range, 0.9 to 23.7 months), and the median OS was 7.4 months (range, 1.4 to 23.7 months). Grade 3 and 4 AEs included anemia (41%), leukopenia (30%), neutropenia (26%), constitutional (26%), and infection (22%). There were no treatment-related deaths. Pemetrexed was well tolerated and demonstrated moderate activity with responses seen in 15% of patients with recurrent carcinoma of the cervix for whom prior chemotherapy had failed. 15 That response rate was similar to the response rate of other agents that have been incorporated into firstline randomized trials.
Lorusso et al 21 evaluated second-line pemetrexed 500 mg/m 2 once every 21 days with folic acid and vitamin B 12 in patients with advanced or recurrent squamous or nonsquamous cervical carcinoma. All patients received prior platinum-based chemotherapy, and most received prior RT (63%). Patients received a median of two cycles (range, one to nine cycles) of pemetrexed. Six patients (14%) IV once every 21 days was selected for this trial. Pemetrexed in combination with cisplatin has demonstrated activity in the treatment of advanced, persistent, or recurrent carcinoma of the cervix. Could cisplatin plus pemetrexed be considered as an alternative to cisplatin plus paclitaxel? The response rate, PFS, and OS reported for the cisplatin doublets tested in GOG-0204, which included a group of patients with better prognosis (PS 0 to 1 only) were cisplatin plus paclitaxel 29%, 6 months, 13 months; cisplatin plus vinorelbine 26%, 4 months, 10 months; cisplatin plus gemcitabine 22%, 5 months, 10 months; and cisplatin plus topotecan 23%, 5 months, 10 months. 24 For cisplatin plus pemetrexed in this study, the response rate was 31%, PFS was 7 months, and OS was 12 months. The toxicity profile for cisplatin plus pemetrexed may be more favorable, with the more serious toxicities (grade 3 and above) being neutropenia 35%, leukopenia 28%, and metabolic 28%. For cisplatin plus paclitaxel, neutropenia 78%, leukopenia 63%, and other hematologic 36% were reported in GOG-0204. 24 The final results of GOG-0240, which also included a group of patients with better prognosis, were recently published. The addition of bevacizumab to cisplatin plus paclitaxel significantly increased response rate from 36% to 48%, PFS from a mean of 5.9 to 8.2 months, and OS from 13.3 to 17 months. 18 Data from other disease sites suggest that bevacizumab can also be combined with cisplatin plus pemetrexed. 47 After it was recognized that the addition of cisplatin to RT increased survival in patients with locally advanced cervical cancer, it was noted that in subsequent recurrences, responses to cisplatin-based chemotherapy were diminished (odds ratio, 0.52; 95% CI, 0.32 to 0.85; P ϭ .009). 48 The substitution of topotecan for cisplatin in combination with paclitaxel was also tested in GOG-0240. Unfortunately, topotecan plus paclitaxel was not superior to cisplatin plus paclitaxel. 49 With cisplatin plus pemetrexed, in this study, responses were noted in 27% of the patients who were previously treated with cisplatin-based chemoradiotherapy and 37% in those who were not.
Pemetrexed combined with cisplatin is an active and tolerable treatment for advanced, persistent, or recurrent carcinoma of the cervix. This combination should be further developed in the treatment of cervical cancer. Given that it may be less toxic than and as active as cisplatin plus paclitaxel and that it can be combined with bevacizumab, comparison of cisplatin-pemetrexed plus bevacizumab with cisplatin-paclitaxel plus bevacizumab would be appropriate. Expression of TS predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancers and could be evaluated as a biomarker in a cervical cancer trial. 50, 51 In addition, the feasibility and safety of concurrent pemetrexed-cisplatin-thoracic RT followed by consolidation pemetrexed-cisplatin for unresectable stage IIIA/B non-small-cell lung cancer has been shown. 52 Thus, it could be tested in cervical cancer.
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